Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Charles River Laboratories International's current 10-Year Share Buyback Ratio was -0.90%.
CRL's 10-Year Share Buyback Ratio is ranked better than 74.44% of 133
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.5
vs CRL: -0.90
Charles River Laboratories International (NYSE:CRL) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Charles River Laboratories International 10-Year Share Buyback Ratio Related Terms
CRL vs RVTY, ICLR, QGEN: 10-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Charles River Laboratories International's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International 10-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's 10-Year Share Buyback Ratio falls into.
Charles River Laboratories International 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -0.90 mean?
Charles River Laboratories International (CRL) has a 10-Year Share Buyback Ratio of -0.90 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Charles River Laboratories International and its competitors. According to the industry distribution chart, Charles River Laboratories International ranks #34 out of 133 companies in the Medical Diagnostics & Research industry, placing it in the top 25.6%.
Is Charles River Laboratories International's 10-Year Share Buyback Ratio too high?
Charles River Laboratories International's current 10-Year Share Buyback Ratio is -0.90. Based on the distribution chart, Charles River Laboratories International ranks #34 out of 133 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's 10-Year Share Buyback Ratio compare to RVTY and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #34 out of 133 companies for 10-Year Share Buyback Ratio. This puts Charles River Laboratories International in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 10-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Charles River Laboratories International and its competitors. Charles River Laboratories International's current 10-Year Share Buyback Ratio is -0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Significantly Overvalued. The stock's GF Value™ is $194.30, compared to a current price of $291.50 — trading 50% above its estimated fair value. The current 10-Year Share Buyback Ratio is -0.90. Charles River Laboratories International's overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current 10-Year Share Buyback Ratio is -0.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $291.50 is trading 50% above its estimated GF Value™ of $194.30.
GuruFocus considers Charles River Laboratories International to be Significantly Overvalued.
Key valuation signals for CRL:
10-Year Share Buyback Ratio: -0.90
GF Value™: $194.30 vs. price of $291.50 (50% above fair value)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for CRL
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
